Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects With Resected Solid Tumors and in Combination With Pembrolizumab in Subjects With Unresectable Solid Tumors

Trial Profile

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects With Resected Solid Tumors and in Combination With Pembrolizumab in Subjects With Unresectable Solid Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Jun 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MRNA 4157 (Primary) ; Pembrolizumab (Primary)
  • Indications Bladder cancer; Colon cancer; Endometrial cancer; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Prostate cancer; Small cell lung cancer; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions; First in man
  • Acronyms KEYNOTE-603
  • Sponsors Moderna Therapeutics
  • Most Recent Events

    • 04 Jun 2019 Results presented at the 55th Annual Meeting of the American Society of Clinical Oncology
    • 01 Jun 2019 According to a Moderna Therapeutics media release, interim data from this study in patients with both resected (adjuvant; n=13) and unresected (advanced; n=20) solid tumors were presented today at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting (Saturday, 1st Jun 2019).
    • 01 Jun 2019 Interim data from this study in patients with both resected (adjuvant; n=13) and unresected (advanced; n=20) solid tumors presented in a Moderna Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top